Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Rule

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Blood|November 3, 2018
Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!Martin Dreyling, Wolfram Klapper, Simon Rule
Expert Review of Hematology|August 28, 2014
Ibrutinib for the treatment of mantle cell lymphomaNimish Shah, Claire Hutchinson, Simon Rule
Hematology/Oncology Clinics of North America|August 31, 2020
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?Rory McCulloch, Toby A Eyre, Simon Rule
Journal of Medical Economics|April 12, 2014
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomSimon Rule, Graham P Collins, Kunal Samanta
Clinical Lymphoma, Myeloma & Leukemia|November 11, 2017
A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell LymphomaMadeliene Parrott, Simon Rule, Michael Kelleher, et al.
Leukemia & Lymphoma|September 13, 2014
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?Nimish Shah, Constantine Tam, John F Seymour, et al.
British Journal of Haematology|October 26, 2012
Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphomaMichelle Furtado, Nimish Shah, Alison Levoguer, et al.
British Journal of Haematology|August 23, 2014
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphomaMichelle Furtado, Rod Johnson, Anton Kruger, et al.
Journal of Cell Communication and Signaling|November 23, 2018
Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphomaAfak Rasheed Salman Zaidi, Sadie Dresman, Charlotte Burt, et al.
Journal of Medical Economics|October 26, 2024
Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphomaLing Cai, Jack Roos, Paulo A P Miranda, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Blood|November 3, 2018
Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!Martin Dreyling, Wolfram Klapper, Simon Rule
Expert Review of Hematology|August 28, 2014
Ibrutinib for the treatment of mantle cell lymphomaNimish Shah, Claire Hutchinson, Simon Rule
Hematology/Oncology Clinics of North America|August 31, 2020
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?Rory McCulloch, Toby A Eyre, Simon Rule
Journal of Medical Economics|April 12, 2014
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomSimon Rule, Graham P Collins, Kunal Samanta
Clinical Lymphoma, Myeloma & Leukemia|November 11, 2017
A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell LymphomaMadeliene Parrott, Simon Rule, Michael Kelleher, et al.
Leukemia & Lymphoma|September 13, 2014
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?Nimish Shah, Constantine Tam, John F Seymour, et al.
British Journal of Haematology|October 26, 2012
Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphomaMichelle Furtado, Nimish Shah, Alison Levoguer, et al.
British Journal of Haematology|August 23, 2014
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphomaMichelle Furtado, Rod Johnson, Anton Kruger, et al.
Journal of Cell Communication and Signaling|November 23, 2018
Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphomaAfak Rasheed Salman Zaidi, Sadie Dresman, Charlotte Burt, et al.
Journal of Medical Economics|October 26, 2024
Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphomaLing Cai, Jack Roos, Paulo A P Miranda, et al.
Pageof 8